Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,517,164
  • Shares Outstanding, K 41,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,990 K
  • 36-Month Beta 2.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.57 +43.83%
on 10/25/17
99.80 -14.15%
on 11/13/17
+22.36 (+35.31%)
since 10/17/17
3-Month
59.57 +43.83%
on 10/25/17
99.80 -14.15%
on 11/13/17
+4.43 (+5.45%)
since 08/17/17
52-Week
44.55 +92.32%
on 01/30/17
99.80 -14.15%
on 11/13/17
+33.48 (+64.14%)
since 11/17/16

Most Recent Stories

More News
Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the...

JPM : 98.14 (-0.34%)
SAGE : 85.68 (+0.01%)
Sage Therapeutics Prices Public Offering of Common Stock

Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the...

JPM : 98.14 (-0.34%)
SAGE : 85.68 (+0.01%)
Sage Therapeutics Announces Proposed Public Offering of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

JPM : 98.14 (-0.34%)
SAGE : 85.68 (+0.01%)
Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.

NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Marinus Pharmaceuticals closed up 14% higher on Thursday after SAGE Therapeutics revealed positive clinical trial data for a postpartum depression...

SAGE : 85.68 (+0.01%)
OTIC : 5.55 (+0.91%)
MRNS : 6.47 (-0.15%)
Today's Research Reports on Stocks to Watch: Aralez Pharmaceuticals and Sage Therapeutics

NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Sage Therapeutics stole the show on Thursday, with gains of over 50% at the close. The company presented positive data with analysts responding...

ARLZ : 1.65 (unch)
SAGE : 85.68 (+0.01%)
EBay and Stericycle slide while Macy's and Fox jump

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:

FOXA : 31.15 (+6.24%)
KSS : 43.72 (+3.48%)
SAGE : 85.68 (+0.01%)
M : 20.35 (+0.49%)
COTY : 17.05 (+1.19%)
OSTK : 52.40 (-3.41%)
SRCL : 62.76 (+0.13%)
Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression

--Brexanolone provided a rapid and durable reduction over 30 days in depressive symptoms as measured by HAM-D in both placebo-controlled multi-center trials

SAGE : 85.68 (+0.01%)
Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced...

SAGE : 85.68 (+0.01%)
Report: Developing Opportunities within Abaxis, PRA Health Sciences, Brighthouse, Investors Bancorp, Cypress Semiconductor, and Sage Therapeutics - Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abaxis, Inc. (NASDAQ:ABAX),...

BHF : 55.67 (+0.45%)
ABAX : 49.37 (+1.86%)
CY : 16.61 (unch)
ISBC : 13.97 (+0.43%)
SAGE : 85.68 (+0.01%)
BHFWV : 64.57 (+0.89%)
PRAH : 80.70 (+1.00%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on November...

SAGE : 85.68 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

2nd Resistance Point 87.88
1st Resistance Point 86.78
Last Price 85.68
1st Support Level 84.99
2nd Support Level 84.30

See More

52-Week High 99.80
Last Price 85.68
Fibonacci 61.8% 78.69
Fibonacci 50% 72.18
Fibonacci 38.2% 65.66
52-Week Low 44.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart